redhillbio.comRedHill Biopharma - Home

Overview Senior Leadership Board of Directors Advisory Board Our Medicines Overview Talicia® Aemcolo® Expanded Access Our Programs Pipeline Pipeline Opaganib Acute Radiation Syndrome COVID-19 RHB-107 COVID-19 RHB-102 Oncology Support Gastroenteritis & Gastritis IBS-D RHB-204 RHB-104 Crohn’s disease Multiple Sclerosis Medical Grant & Investigator Initiated Study Requests Investigator Initiated Study Requests Medical Grant/Sponsorship Medical Information News Investors Overview Events & Presentations Press Releases Financial Filings Quarterly Reports Annual Reports SEC Filings Stock Information Stock Information Analyst Coverage Corporate Governance Governance Documents Partnering Careers Overview Benefits Contact Contact Us Email Alerts HomeOverview Senior Leadership Board of Directors Advisory Board Our Medicines Overview Talicia® Aemcolo® Expanded Access Our Programs Pipeline Pipeline Opaganib Acute Radiation Syndrome COVID-19 RHB-107 COVID-19 RHB-102 Oncology Support Gastroenteritis & Gastritis IBS-D RHB-204 RHB-104 Crohn’s disease Multiple Sclerosis Medical Grant & Investigator Initiated Study Requests Investigator Initiated Study Requests Medical Grant/Sponsorship Medical Information News Investors Overview Events & Presentations Press Releases Financial Filings Quarterly Reports Annual Reports SEC Filings Stock Information Stock Information Analyst Coverage Corporate Governance Governance Documents Partnering Careers Overview Benefits Contact Contact Us Email AlertsInspired by you, focused on your health, and driven to deliver. Learn More Our Medicines Extraordinary medicines. Extraordinary lives. Learn More Pipeline A deep pipeline of innovation. Learn More Innovation in GI and Infectious Diseases RedHill is a specialty pharmaceutical company on a mission to help people live extraordinary lives through the development and commercialization of drugs that address significant unmet medical need. Learn More COVID-19 Response RedHill is at the forefront of the global efforts to combat COVID-19, developing two novel potentially broad-acting, host-directed, late-stage oral therapies, that cover the spectrum of disease severity with expected effect against emerging variants. Learn more about our COVID-19 development programs: Latest News More News Investors See our latest financial information, events, and presentations. Learn More Events View more Events Contact Corporate HQ 21 Ha’arba’a St., Tel-Aviv, Israel, 6473921 Tel: +972-(0)3-541-3131 Fax: +972-(0)3-541-3144 U.S. Commercial Office 8045 Arco Corporate Drive, Suite 200, Raleigh, NC 27617 Tel: +1-984-444-7010 Fax: +1-919-800-3403 +1-919-406-0400[email protected] Quick Links Home About RedHill Our Medicines Our Programs News Investors Partnering Careers Contact Tweets by RedHillBio To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. At RedHill Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. By providing your email address below, you are providing consent to RedHill Biopharma to send you the requested Investor Email Alert updates. * Required Email Address * Mailing Lists * Press Releases Events & Presentations All SEC Filings Quarterly Reports Annual Reports Email Alert Sign Up Confirmation Copyright © 2017- . RedHill Biopharma Ltd. All Rights Reserved. Terms of Use Cookie Policy Privacy Policy Powered By Q4 Inc. 5.122.0.3 (opens in new...